Cartesian Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Carsten Brunn
- Full Time Employees
- 66
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 65 Grove Street Watertown MA United States of America 02472
- IPO Date
- Jun 22, 2016
- CIK
- 0001453687
- Website
- selectabio.com
- Similar Companies
- Business
- Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of mRNA cell therapies for the treatment of autoimmune diseases. The company's core products include Descartes-08, an autologous mRNA CAR-T therapy targeting B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for conditions including generalized myasthenia gravis, systemic lupus erythematosus, and juvenile dermatomyositis, a rare pediatric autoimmune disease. It is also developing Descartes-15, a next-generation autologous anti-BCMA mRNA CAR-T therapy currently in Phase 1 trials for relapsed/refractory multiple myeloma and planned autoimmune indications. Cartesian Therapeutics operates primarily in the United States and is headquartered in Frederick, Maryland. Recent major company developments include a reverse merger completed in November 2023 with Selecta Biosciences, which provided the combined entity with over $110 million in financial resources to advance its therapeutic pipeline. This strategic merger led to a Nasdaq ticker symbol change to RNAC and brought new leadership consolidation combining teams from both companies. Cartesian has progressed its lead candidate Descartes-08 through Phase 2b trials, reporting safety profiles suitable for outpatient administration and ongoing Phase 2 trials in systemic lupus erythematosus, with plans to initiate a pediatric basket trial by the end of 2025. Additionally, Cartesian has advanced the early clinical development of Descartes-15, which shows enhanced CAR expression and selective target killing in preclinical studies and is designed to be administered without preconditioning chemotherapy. The company leverages a proprietary mRNA platform to deliver RNA-engineered chimeric antigen receptor T-cell therapies (rCAR-T) aimed at pathogenic plasma cells secreting autoantibodies that drive autoimmune disorders. Cartesian Therapeutics targets autoimmune disease patients globally, focusing on precision RNA cell therapy innovations and expanding the reach of these novel treatments in clinical-stage development. Founded in 2015, Cartesian Therapeutics continues to pioneer RNA-engineered cell therapy approaches with a robust pipeline and strategic alliances enhancing its operational and financial capacity to support ongoing and future clinical trials.
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Average Price Target from Brokerages
Analyzing Cartesian Therapeutics (NASDAQ:RNAC) and Applied Therapeutics (NASDAQ:APLT)
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Average PT from Brokerages
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $38.50 Consensus Target Price from Brokerages
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Cartesian Therapeutics Announces New Employment Inducement Grants
Contrasting Beyond Air (NASDAQ:XAIR) & Cartesian Therapeutics (NASDAQ:RNAC)
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors